FDA's Largest Infant Formula Testing: What Manufacturers Must Know

The FDA just released results from what it describes as the largest and most rigorous examination of chemical contaminants in infant formula ever conducted in the United States. If you manufacture, co-pack, import, or distribute infant formula — or if you supply ingredients into that supply chain — this is not background news. It is a signal about where FDA's enforcement attention is heading and what your quality systems need to be ready for.

Here is what happened, what the findings mean, and what I think you should do about it before the agency asks you to.

What the FDA Actually Did

This was not a routine market survey. According to the FDA's press announcement, the agency conducted systematic testing of infant formula products available on the U.S. market specifically looking for chemical contaminants — a category that includes heavy metals, environmental contaminants, and other residual chemical substances that can accumulate in food ingredients.

The scope was deliberately broad. FDA sampled across product types, formats, and brands to generate what amounts to a baseline picture of the current contamination landscape. That framing matters: when a regulatory agency invests resources in establishing a baseline, they are usually preparing to use it. A baseline today becomes the benchmark for future enforcement action, import alerts, and warning letters.

The Findings: What the Data Shows

The testing revealed the presence of certain chemical contaminants — including heavy metals such as arsenic, lead, cadmium, and chromium — across a range of infant formula products. Critically, FDA noted that the detected levels were generally low and that the agency did not identify an immediate health risk to infants consuming these products based on the current findings. That is an important distinction, and I want to be careful not to overstate the alarm here.

What the findings do establish, however, is meaningful:

• Chemical contaminants are present at detectable levels in a significant portion of the infant formula market. The question is no longer whether they exist but how consistently manufacturers are monitoring and controlling for them.
• The variation across products is notable. Some products showed higher concentrations than others, which tells FDA — and tells the industry — that manufacturing processes, ingredient sourcing, and supplier qualification practices are not uniform across the market.
• No product-specific recall was announced as a direct result of this testing cycle, but the agency made clear this work will inform future regulatory and policy actions.

One number worth holding onto: FDA's testing program covered a broader range of chemical analytes than any prior infant formula survey — examining dozens of potential contaminants across multiple product categories in a single coordinated effort. That is a meaningful investment of laboratory resources, and it signals sustained institutional attention to this product category.

Why This Matters Beyond the Headlines

The 2022 infant formula shortage — driven largely by the Abbott Sturgis facility shutdown following contamination concerns — exposed how fragile the U.S. infant formula supply chain is and how severe the public health consequences can be when something goes wrong. Congress and FDA both responded with heightened scrutiny, additional resources for oversight, and a clear appetite to prevent a recurrence.

This testing program is part of that response. It sits alongside the Closer to Zero initiative (FDA's action plan to reduce dietary exposure to lead, arsenic, cadmium, and mercury in foods eaten by babies and young children), which established action levels and timelines specifically designed to drive the industry toward cleaner products over time.

The Closer to Zero action levels for lead in infant formula — 10 parts per billion — represent the most specific and enforceable standard FDA has articulated for this category, and manufacturers should treat these as compliance floors, not aspirational targets. Enforcement against products exceeding those levels is a realistic near-term scenario, particularly now that FDA has a robust market dataset to draw from.

In my view, what this testing cycle really does is give FDA the evidentiary foundation it needs to act. It establishes what is "typical" in the market. Anything outside that range now has a documented context for comparison.

How This Compares to Prior FDA Infant Formula Oversight

To appreciate the shift, it helps to see how the oversight landscape has evolved:

The progression is clear. FDA has moved from reactive oversight (respond to complaints and outbreaks) toward proactive, data-driven surveillance. This testing cycle is the most concrete evidence yet of that shift in the infant formula space.

What This Means for Your Compliance Program

Whether you are a large integrated manufacturer or a smaller contract operation, there are practical implications to work through.

Supplier Qualification and Ingredient Sourcing

Heavy metals in finished infant formula do not materialize in the blending room. They arrive with ingredients — particularly with dairy-derived components, grains, and botanicals that accumulate environmental contaminants through soil and water. If your supplier qualification program does not include certificate of analysis (COA) requirements for heavy metal content, or if you are not periodically verifying those COAs through independent third-party testing, you have a gap that FDA's findings make harder to defend.

The question to ask your quality team: can you demonstrate, with documented evidence, that you know the heavy metal profile of every ingredient entering your infant formula production line? If the answer is anything other than a clear yes, that is where to start.

Finished Product Testing

Many manufacturers rely on ingredient-level controls and assume the finished product will be compliant. That assumption has always been thin, and it is thinner now. FDA's market-wide testing creates a de facto expectation that manufacturers have their own finished product data. If FDA finds something in your product through surveillance, you want to be the party who found it first — and who already has a corrective action documented.

Manufacturers who can demonstrate ongoing finished product testing for chemical contaminants, with trend analysis and documented response thresholds, will be in a materially stronger position during an FDA inspection than those who cannot. This is not hypothetical — it is the kind of documentation gap that turns a routine inspection into a Form 483 observation.

Corrective Action Readiness

Given that FDA has now established a baseline for what the market looks like, any manufacturer who receives a test result meaningfully above market norms faces a documented context for regulatory concern. Having a corrective action and preventive action (CAPA) process that specifically addresses contaminant findings — with defined escalation thresholds, supplier notification procedures, and hold/release decision trees — is the difference between demonstrating control and appearing reactive.

The Regulatory Signals Worth Watching

Beyond the immediate findings, there are several forward-looking signals in how FDA framed this announcement.

First, the agency explicitly tied these findings to future policy actions. That language is a preview, not a throwaway. When FDA says testing results will "inform regulatory and policy actions," they typically mean guidance documents, updated action levels, new draft regulations, or enhanced import screening. Manufacturers have a window — and in my experience working with 200+ clients across FDA-regulated industries, that window is rarely as long as people assume.

Second, the Closer to Zero initiative is not finished. FDA has committed to issuing action levels for additional contaminants and additional food categories over time. Infant formula, given its vulnerable consumer population, is almost certainly going to receive continued attention under that framework. The current findings will accelerate that timeline, not slow it.

Third, import scrutiny is likely to increase. A meaningful portion of infant formula ingredients and finished products enter the U.S. through international supply chains. FDA has import alert authority and can detain shipments when surveillance data supports concern. A market-wide dataset that includes imported products gives FDA the evidentiary basis to tighten import screening in ways that would have been harder to justify without it.

What I Recommend Doing Now

I work with companies across the food and dietary supplement space on exactly these kinds of proactive compliance questions, and my honest view is that the manufacturers who come out of this regulatory cycle in the best position will be the ones who treated this announcement as an operational signal rather than background noise.

Here is what I think is worth doing in the near term:

1. Pull your current finished product testing data for heavy metals. If you do not have it, commission testing now, before FDA asks for it. Understanding your own profile is the prerequisite for everything else.

2. Audit your supplier qualification records specifically for contaminant controls. Look for gaps in COA coverage, expired qualification records, and suppliers who have never been asked about their own testing programs for heavy metals.

3. Review your action levels and hold procedures. If your internal thresholds for heavy metals predate the Closer to Zero action levels, they probably need updating. Make sure your quality system reflects current FDA guidance, not the guidance from five years ago.

4. Document your risk assessment. FDA expects manufacturers of infant formula to be operating under a robust preventive controls framework per 21 CFR Part 117 and the specific infant formula requirements under 21 CFR Part 106. A documented risk assessment that specifically addresses chemical contaminants — and that references FDA's current action levels — demonstrates that your quality system is responsive to the current regulatory environment.

5. Consider a gap assessment before your next FDA inspection. If you have not had an outside set of eyes on your infant formula compliance program recently, now is a reasonable time to do that. The landscape has changed enough since 2022 that programs that were adequate then may have visible gaps today.

The Broader Picture

The infant formula category is under more regulatory scrutiny than it has been at any point in the last four decades. The 2022 shortage was a crisis that Congress and the public noticed, and FDA has responded with the kind of sustained attention that tends to produce lasting structural changes in oversight.

This testing cycle is one piece of that. It is significant not just for what it found, but for what it demonstrates about FDA's intentions and capabilities going forward. The agency now has a market-wide contaminant dataset for infant formula. They will use it.

For manufacturers operating in this space, the question is not whether FDA is paying attention. It clearly is. The question is whether your quality systems are ready for the scrutiny that attention brings — and whether you are going to find out the answer on your own terms or on FDA's.

If you want to talk through what this means for your specific program, reach out to Certify Consulting. We have helped more than 200 clients navigate exactly these kinds of proactive compliance questions, and we have a 100% first-time audit pass rate because we work through the gaps before the inspector arrives.

For more on how FDA's preventive controls framework applies to your operations, see our FDA Preventive Controls compliance resources on thefdaexpert.com.

Source: FDA Press Announcement — "FDA Releases Results from Largest-Ever Testing of Infant Formula in the U.S." Available at fda.gov.

Last updated: 2026-07-22